The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Open accessAbstract
Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationLlovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Self-citationMor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984) · Cancer · doi:10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w · Cited by 1,067
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Self-citationThe Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Venook, A. P., Papandreou, C., Furuse, J., & Ladrón de Guevara, L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-05 · Cited by 965
Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
Shiina, S., Tateishi, R., Arano, T., Uchino, K., Enooku, K., Nakagawa, H., Asaoka, Y., Sato, T., Masuzaki, R., Kondo, Y., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.425 · Cited by 724
Thomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., Gores, G., Kerlan, R., Merle, P., O'Neil, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7805 · Cited by 394
Makuuchi, M., Kokudo, N., Arii, S., Futagawa, S., Kaneko, S., Kawasaki, S., Matsuyama, Y., Okazaki, M., Okita, K., Omata, M., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00216.x · Cited by 294
Cabrera, R. (2012) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s16316 · Cited by 274
Practice guidelines for management of hepatocellular carcinoma 2009
Korean Liver Cancer Study Group and National Cancer Center, K. (2009) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2009.15.3.391 · Cited by 257
Epidemiology and Management of Hepatocellular Carcinoma
Yang, J. D., & Roberts, L. R. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.07.004 · Cited by 213
Self-citationCancer Control Activities in the Republic of Korea
Yoo, K.-Y. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn026 · Cited by 203
Korean Liver Cancer Study Group (KLCSG), & National Cancer Center, K. (. (2015) · Korean Journal of Radiology · doi:10.3348/kjr.2015.16.3.465 · Cited by 201
Kudo, M., & Okanoue, T. (2007) · Oncology · doi:10.1159/000111702 · Cited by 196
Self-citationCancer Epidemiology and Control in Taiwan: a Brief Review
Chen, C.-J., You, S.-L., Lin, L.-H., Hsu, W.-L., & Yang, Y.-W. (2002) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hye138 · Cited by 185
Lencioni, R. A., Chen, X., Dagher, L., & Venook, A. P. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-42 · Cited by 153
Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance
Yang, J. D., Harmsen, W. S., Slettedahl, S. W., Chaiteerakij, R., Enders, F., Therneau, T. M., Orsini, L. S., Kim, W. R., & Roberts, L. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.027 · Cited by 132
Self-citationSloane, D. A., Chen, H., & Howell, C. D. (2006) · PubMed · Cited by 123
Song, P., Gao, J., Inagaki, Y., Kokudo, N., Hasegawa, K., Sugawara, Y., & Tang, W. (2013) · Liver Cancer · doi:10.1159/000346220 · Cited by 105
Hepatitis B vaccination in children: The Taiwan experience
Ni, Y., & Chen, D. (2010) · Pathologie Biologie · doi:10.1016/j.patbio.2009.11.002 · Cited by 100
Liver Cancer Working Group Report
Kudo, M., Han, K., Kokudo, N., Cheng, A., Choi, B. I., Furuse, J., Izumi, N., Park, J.-W., Poon, R. T. P., & Sakamoto, M. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq123 · Cited by 72
Self-citationTargeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma
Wei, Z., Doria, C., & Liu, Y. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7633 · Cited by 29
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Metadata
- Authors
- Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., & Sherman, M.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2015-03-25
- Volume
- 35
- Issue
- 9
- Pages
- 2155-2166
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2028319026
- Cited by
- 1,245
- References
- 35
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.